Supplementary Figure 2 from IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy
Imianowski CJ., Kuo P., Whiteside SK., von Linde T., Wesolowski AJ., Conti AG., Evans AC., Baird T., Morris BI., Fletcher NE., Yang J., Poon E., Lakins MA., Yamamoto M., Brewis N., Morrow M., Roychoudhuri R.
<p>Supplementary Figure 2: T cell populations in the spleen and tumor of FS120m treated mice. (A) Percentages of indicated T cell populations in the tumors of mice treated with FS120m or control antibodies. (B) Percentages of indicated T cell populations in the spleens of mice treated with FS120m or control antibodies. (C) Absolute counts of exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m treated animals. (D) Absolute counts of IFN-γ producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. (E) Absolute counts of TNF producing exTreg cells and Foxp3+ RFP+ Treg cells per gram of tumors (left) and in whole spleens (right) of FS120m-treated animals. * P ≤ 0.05, ** P ≤ 0.01. Student’s t test. Bars and error are mean and s.e.m.</p>